These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 34771642)

  • 1. Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers.
    McFadden M; Singh SK; Oprea-Ilies G; Singh R
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comprehensive Review on Current Treatments and Challenges Involved in the Treatment of Ovarian Cancer.
    Saman S; Srivastava N; Yasir M; Chauhan I
    Curr Cancer Drug Targets; 2024; 24(2):142-166. PubMed ID: 37642226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons.
    Majidinia M; Mirza-Aghazadeh-Attari M; Rahimi M; Mihanfar A; Karimian A; Safa A; Yousefi B
    IUBMB Life; 2020 May; 72(5):855-871. PubMed ID: 31913572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoplatform-based natural products co-delivery system to surmount cancer multidrug-resistant.
    Liang Y; Liu ZY; Wang PY; Li YJ; Wang RR; Xie SY
    J Control Release; 2021 Aug; 336():396-409. PubMed ID: 34175367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
    Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
    Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
    Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
    Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanodrug delivery in reversing multidrug resistance in cancer cells.
    Kapse-Mistry S; Govender T; Srivastava R; Yergeri M
    Front Pharmacol; 2014; 5():159. PubMed ID: 25071577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
    Glackin CA
    Enzymes; 2018; 44():83-101. PubMed ID: 30360816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
    Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
    Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting DNA Repair in Ovarian Cancer Treatment Resistance.
    Wong-Brown MW; van der Westhuizen A; Bowden NA
    Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):518-526. PubMed ID: 32253106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study.
    Kobayashi E; Iyer AK; Hornicek FJ; Amiji MM; Duan Z
    Clin Orthop Relat Res; 2013 Mar; 471(3):915-25. PubMed ID: 23011844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nano-based strategies to overcome p-glycoprotein-mediated drug resistance.
    Niazi M; Zakeri-Milani P; Najafi Hajivar S; Soleymani Goloujeh M; Ghobakhlou N; Shahbazi Mojarrad J; Valizadeh H
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1021-33. PubMed ID: 27267126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance.
    Karthikeyan S; Hoti SL
    Anticancer Agents Med Chem; 2015; 15(5):605-15. PubMed ID: 25584696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
    Erin N; Grahovac J; Brozovic A; Efferth T
    Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer.
    Ren F; Shen J; Shi H; Hornicek FJ; Kan Q; Duan Z
    Biochim Biophys Acta; 2016 Dec; 1866(2):266-275. PubMed ID: 27717733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
    Aghamiri S; Mehrjardi KF; Shabani S; Keshavarz-Fathi M; Kargar S; Rezaei N
    Nanomedicine (Lond); 2019 Aug; 14(15):2083-2100. PubMed ID: 31368405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment.
    van Zyl B; Tang D; Bowden NA
    Endocr Relat Cancer; 2018 May; 25(5):R303-R318. PubMed ID: 29487129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticle delivery systems to combat drug resistance in ovarian cancer.
    Miller EM; Samec TM; Alexander-Bryant AA
    Nanomedicine; 2021 Jan; 31():102309. PubMed ID: 32992019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.